Dr Reddy’s Labs launches Trientine Hydrochloride Capsules USP, 250 mg, in US Market

MUMBAI, Feb 7: Pharma Major Dr Reddy’s Laboratories on Friday announced the launch of Trientine Hydrochloride Capsules USP, 250 mg, a therapeutically equivalent generic version of Syprine (trientine hydrochloride) Capsules, approved by the US Food and Drug Administration (USFDA).
”We are pleased to provide this convenient alternative for patients, pharmacists and distribution partners,” explains Marc Kikuchi, Chief Executive Officer and Head of Dr. Reddy’s North America Generics. “Our product can be stored at room temperature (20?C to 25?C or 68? F to 77?F) throughout the product shelf life of 24 months,” the company said in a filing with BSE.
The Syprine brand and generic prududl had US sales or approximately USD94.2 million MAT for the most recent twelve months ending in December 2019 according to IMS Health.
Dr Reddy’s Trientine Hydrochloride Capsules USP, 250 mg are available in 100 count bottles. Syprine is a trademark of Alton Pharma. (UNI)

LEAVE A REPLY

Please enter your comment!
Please enter your name here